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OBJECTIVE—Experimental and clinical studies have suggested
that uric acid may contribute to the development of hypertension
and kidney disease. Whether uric acid has a causal role in the
development of diabetic nephropathy is not known. The objec-
tive of the present study is to evaluate uric acid as a predictor of
persistent micro- and macroalbuminuria.
RESEARCH DESIGN AND METHODS—This prospective ob-
servational follow-up study consisted of an inception cohort of
277 patients followed from onset of type 1 diabetes. Of these, 270
patients had blood samples taken at baseline. In seven cases,
uric acid could not be determined; therefore, 263 patients (156
men) were available for analysis. Uric acid was measured 3
years after onset of diabetes and before any patient developed
microalbuminuria.
RESULTS—During a median follow-up of 18.1 years (range
1.0–21.8), 23 of 263 patients developed persistent macroalbumin-
uria (urinary albumin excretion rate 300 mg/24 h in at least two
of three consecutive samples). In patients with uric acid levels in
the highest quartile (249 mol/l), the cumulative incidence of
persistent macroalbumnuria was 22.3% (95% CI 10.3–34.3) com-
pared with 9.5% (3.8–15.2) in patients with uric acid in the three
lower quartiles (log-rank test, P  0.006). In a Cox proportional
hazards model with sex and age as ﬁxed covariates, uric acid was
associated with subsequent development of persistent mac-
roalbuminuria (hazard ratio 2.37 [95% CI 1.04–5.37] per 100
mol/l increase in uric acid level; P  0.04). Adjustment for
confounders did not change the estimate signiﬁcantly.
CONCLUSIONS—Uric acid level soon after onset of type 1
diabetes is independently associated with risk for later develop-
ment of diabetic nephropathy. Diabetes 58:1668–1671, 2009
D
iabetes is the leading cause of end-stage renal
disease (ESRD) in the Western world, and the
number of patients diagnosed each year with
ESRD due to diabetes is rising (1). The complex
pathogenesis for the development of diabetic nephropathy
is not fully understood (2). One factor that has been
associated with cardiovascular and renal disease is serum
uric acid. Recently, experimental and clinical studies have
suggested that uric acid may contribute to the develop-
ment of hypertension, the metabolic syndrome, and kidney
disease (3). The role of uric acid in the development of
diabetic nephropathy is not understood. The objective of
the present study is therefore to evaluate uric acid as a
predictor of persistent micro- and macroalbuminuria in an
inception cohort of type 1 diabetic patients followed from
onset of diabetes.
RESEARCH DESIGN AND METHODS
All newly diagnosed type 1 diabetic patients, consecutively admitted to the
Steno Diabetes Center between 1 September 1979 and 31 August 1984, were
included in an inception cohort (n  277), described previously in detail (4).
Diagnosis in all patients included measurement of fasting C-peptide. A total of
270 patients had blood samples taken at baseline. In seven cases, uric acid was
not determined; therefore, 263 patients (156 men) were available for analysis.
Uric acid was measured 3 years after onset of diabetes and before any patient
developed microalbuminuria.
Patients were treated according to set principles and guidelines as de-
scribed previously (4,5). No speciﬁc intervention was carried out. A1C was
measured from venous blood samples, with a normal range of 4.1–6.4% (4).
Each patient had a 24-h urinary albumin excretion rate (UAER) measured at
least once per year. UAER was quantitated by using automated immunotopical
nephelometric analysis until 1984 (6) and by using enzyme immunoassay from
1984 to 1997 (7) (sensitivity 1.1 mg/l; coefﬁcient of variation [CV] 8%). From
1997, the DAKO Turbidimetric method was used to measure UAER with a CV
of 5%. A very close correlation between radial immunodiffusion and enzyme
immunoassay (r  0.99) as well as between enzyme immunoassay and the
turbidimetric method (r  0.99) was documented, and absence of any
systematic error between methods was veriﬁed by Bland-Altman plots before
any change in methods was imposed. Persistent microalbuminuria and
macroalbuminuria were deﬁned as UAER of 30–300 mg/24 h and 300 mg/24
h, respectively, in at least two of three consecutive samples, with 30%
increase in UAER above the baseline level (4).
Uric acid was measured from samples that had been stored in freezers at
20°C by colorimetric slide test (Vitros 5.1 FS; Ortho Clinical Diagnostics),
with a CV of 1.3 and 1.5%, respectively, in samples from the lowest and highest
quartiles of the uric acid levels. Measurements were from samples taken 3
years after onset of diabetes in all subjects, i.e., after initial glycemic
stabilization, and prior to development of persistent microalbuminuria. At the
time of sampling, only two patients received antihypertensive treatment (both
treated with diuretics; one additionally treated with an ACE inhibitor). The
normal range of uric acid was 200–450 mol/l in men and 150–350 mol/l in
women.
Arterial blood pressure was measured at least once per year with a
standard mercury sphygmomanometer and was performed with the patient in
a seated position after 10 min rest. Smoking history was determined via
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more than one cigarette per day. Retinopathy was graded as absent, nonpro-
liferative, or proliferative (5). All patients provided informed consent for the
participation in the study.
Statistical analysis. Variables with skewed distribution are median (inter-
quartile range); all other values are given as means  SD. For non–normally
distributed variables, comparisons between groups were performed using the
Mann-Whitney U test, whereas one-way ANOVA or unpaired Student’s t tests
were used for normally distributed variables. A 
2 test was used for compar-
ison between groups of noncontinuous variables. To evaluate uric acid as a
causal determinant of development of persistent micro- or macroalbuminuria
in an explanatory model, a Cox proportional hazards regression model was
used, including baseline levels of variables that either previously had been
shown to be associated with the level of uric acid or were correlated with uric
acid in the present study, correcting for different lengths of follow-up. Uric
acid was entered in the model as a continuous variable. Because both sex and
age can affect the outcome (development of nephropathy) and the indepen-
dent variable (uric acid), sex and age were entered as ﬁxed variables in the
models. These models allow for adjustment for sex differences, which is
practical because the different reference intervals between sexes can be
disregarded when only evaluating risk without ﬁrm cutoff values.
The cumulative incidence of persistent micro- and macroalbuminuria was
calculated based on the entire follow-up period with a life-table method.
Groups were compared using the log-rank test. Statistical signiﬁcance was
assumed for P  0.05. All statistical calculations were performed with SPSS
for Windows, version 15.0 (SPSS, Chicago, IL).
RESULTS
The 263 patients were followed for a median of 18.1 years
(interquartile range 1.0–21.8). Of these, 72 patients pro-
gressed to persistent microalbuminuria and 23 progressed
further to persistent macroalbuminuria. This resulted in a
cumulative incidence of persistent microalbuminuria of
32.2% (95% CI 25.7–38.7) and a cumulative incidence of
macroalbuminuria of 12.6% (7.3–17.9). Clinical character-
istics of the diabetic patients at baseline, deﬁned as 3 years
after onset of diabetes, are summarized in Table 1. No
patients had diabetic retinopathy at baseline.
All patients had serum uric acid values within the
reference interval. However, within the normal range, a
signiﬁcant difference in the means  SD level of uric acid
3 years after onset of diabetes and before any patient
developed micro- or macroalbuminuria was found when
comparing the three groups. In a one-way ANOVA test
comparing the mean levels of uric acid in the three groups,
there was a trend toward an overall difference among
groups; P  0.063 (Table 1). Looking at the differences
between each group separately, the mean level of serum
uric acid was signiﬁcantly higher in patients who eventu-
ally progressed to persistent macroalbuminuria (239.1 
61 mol/l) versus patients remaining normoalbuminuric
(209.4  57.8 mol/l) or later progressing to microalbu-
minuria only (210.7  55.9 mol/l); P  0.05 for all
comparisons. Importantly, no differences in serum creati-
nine were apparent among groups (Table 1).
Development of microalbuminuria. When comparing
patients progressing to microalbuminuria as a combined
group irrespective of later or no progression to macroalbu-
minuria versus patients remaining normoalbuminuric, no
difference in the mean  SD level of uric acid 3 years after
onset of diabetes was found (219.8  58.7 mol/l in
patients later progressing to persistent micro- or mac-
roalbuminuria vs. 209.4  56.8 mol/l in patients with
persistent normoalbuminuria; P  0.194).
In a Cox proportional hazards model with sex and age as
ﬁxed covariates, uric acid was not independently associ-
ated with subsequent development of persistent mi-
croalbuminuria (hazard ratio [HR] 1.05 [95% CI 0.66–1.69]
per 100 mol/l increase in uric acid level; P  0.83).
Adjustments for baseline level of BMI, glycemic control,
UAER, serum creatinine, serum cholesterol, and mean
arterial blood pressure did not change the estimate
signiﬁcantly.
Development of macroalbuminuria. In a Cox propor-
tional hazards model with sex and age as ﬁxed covariates,
uric acid was independently associated with subsequent
development of persistent macroalbuminuria (HR 2.37
[95% CI 1.04–5.37] per 100 mol/l increase in uric acid
level; P  0.04). Adjustment for baseline level of BMI,
glycemic control, UAER, serum creatinine, serum choles-
terol, and mean arterial blood pressure did not change the
estimate signiﬁcantly (adjusted HR 2.93 [1.25–6.86] per
100 mol/l increase in uric acid level; P  0.013). In
patients with uric acid levels in the highest quartile
(249 mol/l but within the normal range), the cumu-
lative incidence of persistent macroalbuminuria was
22.3% (10.3–34.3) compared with 9.5% (3.8–15.2) in
patients with uric acid in the three lower quartiles
(crude log-rank test, P  0.006; after Bonferroni correc-
tion, P  0.012) (Fig. 1).
TABLE 1
Characteristics of 263 type 1 diabetic patients followed from onset of diabetes divided into patients with persistent normoalbumin-
uria, patients who later progressed to microalbuminuria, and patients who later progressed to microalbuminuria and further to
macroalbuminuria
Persistent
normoalbuminuria Microalbuminuria Macroalbuminuria P
n 191 49 23
Male sex (n/%) 107/56 33/67 16/70 0.21
Height (cm) 172  13 168  16 171  11 0.10
Weight (kg) 60.6  13.3 58.5  17.0 63.1  13.4 0.41
Age (years) 28  13 29  18 28  13 0.88
Systolic blood pressure (mmHg) 122  16 129  20 128  15 0.009
Diastolic blood pressure (mmHg) 76  10 80  13 81  10 0.016
UAER (mg/24 h) 8 (5–13) 11 (7–17) 11 (8–16) 0.004
A1C (%) 9.7  2.2 10.2  1.8 10.1  2.0 0.36
Serum cholesterol (mmol/l) 5.4  1.5 5.5  1.4 5.9  1.5 0.359
Serum creatinine (mol/l) 80  15 77  16 79  13 0.443
Serum uric acid (mol/l) 209.4  57.8 210.7  55.9 239.1  61.0 0.063
Data are mean  SD or median (interquartile range) unless otherwise indicated. Data are from 3 years after onset of diabetes. P values are
overall comparison between the three groups.
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In the present prospective observational study of an
inception cohort followed from onset of type 1 diabetes
and for a median of 18 years, uric acid was not a predictor
of persistent microalbuminuria. In contrast, we demon-
strate that the level of uric acid early in the course of type
1 diabetes is signiﬁcantly and independently associated
with later development of persistent macroalbuminuria. A
signiﬁcantly higher proportion of patients developing
overt nephropathy among patients with serum uric acid in
the highest quartile at baseline was found. These results
support the idea that uric acid may be involved in the
pathogenesis of microvascular complications in diabetes.
Hyperuricemia may be a marker of or by itself be
responsible for microvascular disease through stimulation
of the renin angiotensin system and inhibition of endothe-
lial nitric oxide (8). Animal models of induced hyperurice-
mia have demonstrated an association with renal disease
(9–11). In humans, hyperuricemia has been associated
with hypertension and, recently, with initiation and pro-
gression of nondiabetic renal disease (3,8,12). In those
with diabetes, Rosolowsky et al. (13) have reported
from a cross-sectional study that serum uric acid in the
high-normal range was associated with impaired renal
function in patients with type 1 diabetes and normo- or
microalbuminuria.
Thus far, no studies have evaluated the impact of uric
acid on the development of diabetic kidney disease. In our
present study of 263 type 1 diabetic patients followed from
onset of diabetes, we were able to demonstrate that the
level of uric acid early in the course of type 1 diabetes is
signiﬁcantly associated with later development of diabetic
kidney disease, but we could not establish an association
with persistent microalbuminuria. However, patients pro-
gressing to microalbuminuria may be a more heterogenous
group than previously assumed, which could explain why
the level of uric acid was not elevated in the microalbu-
minuric patients as such. Our data suggest that uric acid
may only be elevated in the progressors. Our ﬁndings in
the present study emphasize the importance of the use of
a solid and robust end point when evaluating risk markers
for disease.
The patients in our inception cohort are unselected, all
type 1 diabetic patients irrespective of age at diagnosis
were included, and our population has a higher mean age
than other studies of type 1 diabetic patients. Conse-
quently, our results cannot be directly generalized to
patients with type 1 diabetes, and earlier onset of disease
but must be validated in such populations. As only two
patients received antihypertensive treatment at the time of
sampling for measurement of uric acid, the level of uric
acid is unlikely to be confounded by use of diuretics in our
population. One limitation in the present study is that
clinical blood pressure measurements were used. Clearly,
a more precise method, such as ambulatory blood pres-
sure measurements over 24 h (14), reduces variability in
measurement and makes estimates more precise. Genetic
factors inﬂuencing the level of uric acid (15) or other
unknown factors not measured in our study may have an
impact on the relationship between uric acid and the
development of diabetic nephropathy. The possibility of
sublimation of the frozen and stored samples cannot be
ruled out. However, if sublimation occurred, this would
affect all samples, and patients with high values would still
have high values within the same population, although at a
lower level.
Diabetic kidney disease is strongly associated with
cardiovascular mortality (16) and may reﬂect a more
generalized vascular process (17). Elevated uric acid not
only has been demonstrated to be associated with kidney
disease but also has been linked to endothelial dysfunc-
tion, development of hypertension, and cardiovascular
disease irrespective of renal involvement (3). Elevated
uric acid may be a candidate for a common link between
micro- and macrovascular disease in diabetic patients.
In conclusion, we found levels of circulating uric acid in
the higher end of the normal range to be an independent
predictor for development of overt diabetic nephropathy,
thus supporting the concept that uric acid may be involved
in the pathogenesis of diabetic microvascular complica-
tions. Consequently, our study suggests that a long-term
treatment trial with allopurinol is warranted.
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